DHR Strangle Strategy
DHR (Danaher Corporation), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.
DHR (Danaher Corporation) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $117.48B, a trailing P/E of 31.85, a beta of 0.84 versus the broader market, a 52-week range of 163.32-242.8, average daily share volume of 4.5M, a public-listing history dating back to 1978, approximately 61K full-time employees. These structural characteristics shape how DHR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.84 places DHR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. DHR pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on DHR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current DHR snapshot
As of May 15, 2026, spot at $161.24, ATM IV 30.61%, IV rank 43.10%, expected move 8.78%. The strangle on DHR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on DHR specifically: DHR IV at 30.61% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.78% (roughly $14.15 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DHR expiries trade a higher absolute premium for lower per-day decay. Position sizing on DHR should anchor to the underlying notional of $161.24 per share and to the trader's directional view on DHR stock.
DHR strangle setup
The DHR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DHR near $161.24, the first option leg uses a $170.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DHR chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DHR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $170.00 | $2.15 |
| Buy 1 | Put | $155.00 | $2.78 |
DHR strangle risk and reward
- Net Premium / Debit
- -$492.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$492.50
- Breakeven(s)
- $150.08, $174.93
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
DHR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on DHR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$15,006.50 |
| $35.66 | -77.9% | +$11,441.51 |
| $71.31 | -55.8% | +$7,876.51 |
| $106.96 | -33.7% | +$4,311.52 |
| $142.61 | -11.6% | +$746.52 |
| $178.26 | +10.6% | +$333.47 |
| $213.91 | +32.7% | +$3,898.47 |
| $249.56 | +54.8% | +$7,463.46 |
| $285.21 | +76.9% | +$11,028.46 |
| $320.86 | +99.0% | +$14,593.45 |
When traders use strangle on DHR
Strangles on DHR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DHR chain.
DHR thesis for this strangle
The market-implied 1-standard-deviation range for DHR extends from approximately $147.09 on the downside to $175.39 on the upside. A DHR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current DHR IV rank near 43.10% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on DHR should anchor more to the directional view and the expected-move geometry. As a Healthcare name, DHR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DHR-specific events.
DHR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DHR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DHR alongside the broader basket even when DHR-specific fundamentals are unchanged. Always rebuild the position from current DHR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on DHR?
- A strangle on DHR is the strangle strategy applied to DHR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With DHR stock trading near $161.24, the strikes shown on this page are snapped to the nearest listed DHR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DHR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the DHR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 30.61%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$492.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DHR strangle?
- The breakeven for the DHR strangle priced on this page is roughly $150.08 and $174.93 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DHR market-implied 1-standard-deviation expected move is approximately 8.78%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on DHR?
- Strangles on DHR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DHR chain.
- How does current DHR implied volatility affect this strangle?
- DHR ATM IV is at 30.61% with IV rank near 43.10%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.